Moderna stock plunges 18% after company lowers 2025 sales forecast by $1 billion
Posted: Jan 13, 2025
- Moderna lowered its 2025 sales guidance by $1 billion, now expecting revenue between $1.5 billion and $2.5 billion.
- Moderna's share price fell 18% in premarket trading, impacting other vaccine stocks like Novavax, BioNTech, and Pfizer.
- Factors contributing to lower sales include increased competition, falling vaccination rates, and uncertainty around manufacturing contracts and CDC recommendations.
- Moderna plans to reduce 2025 cash expenses by $1 billion and seek additional cost reductions in 2026.
- The company aims to diversify its portfolio, with plans for 10 new product approvals in the next three years.
- Moderna is focused on expanding its mRNA platform for future vaccine development.
- Moderna lowered its 2025 sales guidance by $1 billion, now expecting revenue between $1.5 billion and $2.5 billion
- Majority of sales will come from Covid shot and newly launched vaccine for respiratory syncytial virus
- Shares of $MRNA plunged 18% in premarket trading
- Factors weighing on sales include increased competition in the Covid market and falling vaccination rates
- Moderna plans to reduce cash cost expenses and invest in diversifying its portfolio
- Company aims for 10 new product approvals over the next three years, including a combination shot for Covid and the flu.
What do people on Reddit think?
🚨 Reddit sentiment: mixed/negative - Comments show a mix of criticism on executive actions, the company's strategic direction, and concerns on the ongoing reliance on COVID-related products, with a few individuals still considering investing. Summarized comments: - Moderna's stock price has fallen significantly, highlighting past high values of $450 per share. - The company's heavy investment in COVID is questioned, suggesting it needs a new direction and revenue stream. - There are sarcastic comments on Moderna's potential actions to boost stock prices, such as releasing a new strain of COVID. - Concerns are raised about executive stock sales during the COVID years. - Comments reflect uncertainty about the meaning of reducing 2025 cash cost expenses by $1 billion. - Some investors are still engaged with Moderna, for example, being assigned 100 shares from selling options. - Negative comments regarding the vaccine's side effects, hinting at possible lawsuits. Stock tickers discussed: $MRNA
Stay ahead of the market with AI stock alerts & AI summaries of the latest earnings, stock ideas for free with Fluid Bot. Sign up now!